1. Protease resistance of ex vivo amyloid fibrils implies the proteolytic selection of disease-associated fibril morphologies
- Author
-
Bouke P. C. Hazenberg, Stefan Schoenland, Bernd Reif, Tejaswini Pradhan, Christian Haupt, M. Faendrich, J. Schoenfelder, Johan Bijzet, Ute Hegenbart, P. B. Pfeiffer, and Translational Immunology Groningen (TRIGR)
- Subjects
PROTEINS ,medicine.medical_treatment ,proteolytic stability ,macromolecular substances ,Fibril ,prion ,Amyloid disease ,Internal Medicine ,medicine ,Serum amyloid A ,protein misfolding ,immunoglobulin light chain ,GLYCOSAMINOGLYCANS ,chemistry.chemical_classification ,Protease ,biology ,Chemistry ,serum amyloid A ,Amyloid fibril ,TRANSTHYRETIN ,In vitro ,POLYMORPHISM ,Amino acid ,Transthyretin ,Amyloid structure ,biology.protein ,Biophysics ,Protein folding ,Ex vivo - Abstract
Several studies recently showed that ex vivo fibrils from patient or animal tissue were structurally different from in vitro formed fibrils from the same polypeptide chain. Analysis of serum amyloid A (SAA) and Aβ-derived amyloid fibrils additionally revealed that ex vivo fibrils were more protease stable than in vitro fibrils. These observations gave rise to the proteolytic selection hypothesis that suggested that disease-associated amyloid fibrils were selected inside the body by their ability to resist endogenous clearance mechanisms. We here show, for more than twenty different fibril samples, that ex vivo fibrils are more protease stable than in vitro fibrils. These data support the idea of a proteolytic selection of pathogenic amyloid fibril morphologies and help to explain why only few amino acid sequences lead to amyloid diseases, although many, if not all, polypeptide chains can form amyloid fibrils in vitro.
- Published
- 2021